FDA Accepts Dyne Therapeutics' BLA for Duchenne Muscular Dystrophy Treatment
The U.S. FDA has accepted Dyne Therapeutics' (DYN) Biologics License Application (BLA) for z-rostudirsen, a treatment for Duchenne muscular dystrophy. The application is under priority review with an action date set for January 21, 2027.
Tickers: $DYN
Topics: BLA acceptance drug approval Duchenne muscular dystrophy